ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The journal is published by BMJ on behalf of ESMO. http://esmoopen.bmj.com/ * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
We evaluated the applicability of the scale and assessed the reasonableness of the generated scores in early breast cancer. Form 1 of the ESMO-MCBS v1...
Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) serves to grade therapies with curative intent. Fo...
The therapeutic landscape in melanoma is evolving rapidly. In this podcast, Jonathan Lim (a member of the ESMO Young Oncologists Committee) interviews...
The advent of cancer immunotherapy has radically changed the field of oncology by improving the way many malignancies, including several aggressive an...
The Covid-19 pandemic is currently active all over Europe and especially in Italy. In this podcast Anna Berghoof discusses with Matteo Lambertini - De...
Advanced cholangiocarcinoma is associated with a particular impaired survival prognosis. So far targeted therapies with relevant clinical efficacy are...
Glioblastoma is the most frequent primary malignant brain tumor in adults. Methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) promotor ...
There has been a lot of exciting trials in lung cancer reported in 2019. In this podcast, Jonathan Lim (YOC member) speaks to Professor Sanjay Popat a...
Immunotherapy approaches have revolutionized medical oncology in the last years. However, still only a fraction of patients is responding. Given the r...
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. The phase III trial Osi...